Doxycycline injection 100 mg/10mL Single Dose Vials, Preservative free 10/Box (RX)

Doxycycline for Injection 100 mg is a sterile, lyophilized (powder) tetracycline‑class antibiotic intended for intravenous (IV) use after reconstitution and dilution. Each single‑dose vial contains doxycycline hyclate equivalent to 100 mg of doxycycline base. It is typically used in hospital and clinical settings when oral doxycycline is not appropriate (e.g., patient cannot swallow, severe or acute infections requiring IV therapy). What It Is Used For Doxycycline for Injection is indicated for the treatment of a wide range of infections caused by susceptible organisms, including: Respiratory tract infections Community‑acquired pneumonia, bronchitis, and other lower respiratory infections due to susceptible bacteria. Skin and skin structure infections Cellulitis, wound infections, and other soft tissue infections caused by susceptible organisms. Intra‑abdominal and gynecologic infections As part of appropriate combination regimens for polymicrobial infections where anaerobes and atypical organisms may be involved. Rickettsial and tick‑borne infections Rocky Mountain spotted fever, Mediterranean spotted fever, and other rickettsioses. Lyme disease (Borrelia burgdorferi) and certain other tick‑borne infections where doxycycline is the drug of choice. Zoonotic and unusual infections (where doxycycline is often first‑line) Q fever, psittacosis/ornithosis, certain forms of brucellosis (in combination regimens), and other infections when the causative organism is known or strongly suspected to be susceptible. Serious infections when oral therapy is not feasible When a patient is unable to take oral doxycycline or requires parenteral therapy due to severity, GI intolerance, or NPO status. Use should be guided by culture and susceptibility data, local antibiograms, and current clinical guidelines wherever possible, and reserved for infections where doxycycline is an appropriate choice to help limit the development of antimicrobial resistance. Key Product Characteristics Dosage form: Lyophilized powder for injection Strength: 100 mg per vial (reconstituted to 10 mg/mL with 10 mL diluent, per labeling) Route: Intravenous infusion only (after proper dilution; not for intramuscular injection) Packaging: 10 single‑dose vials per box Usage setting: Prescription product for use by or under the supervision of licensed healthcare professionals 1. For Professional Use Only Prescription‑only medication. Reconstitution, dilution, and administration must follow the official prescribing information and institutional protocols. Not intended for self‑administration or home compounding by patients. 2. Reconstitution, Dilution & Administration Each vial must be reconstituted with an appropriate diluent (e.g., Sterile Water for Injection) and further diluted in a compatible IV fluid before infusion. Infuse slowly via IV to minimize risk of local venous irritation or thrombophlebitis. Refer to the Par/Par Pharmaceutical package insert for: Exact diluents and volumes Final concentration and compatible IV solutions Maximum recommended infusion rates Stability and storage times after preparation Do not use vials if there is particulate matter, discoloration, or compromised integrity. 3. Contraindications & Major Precautions Contraindicated in patients with known hypersensitivity to: Doxycycline Other tetracyclines (e.g., tetracycline, minocycline) Pregnancy and breastfeeding: Tetracyclines can cross the placenta and are generally avoided during pregnancy, especially in later trimesters, due to risk of effects on fetal bones and teeth. Use in nursing mothers requires a careful risk–benefit assessment. Pediatric use: Tetracyclines may cause permanent tooth discoloration and enamel hypoplasia and can affect bone growth in children. Generally not recommended in children under 8 years, except for serious or life‑threatening conditions where benefits clearly outweigh risks (e.g., Rocky Mountain spotted fever, inhalational anthrax, severe tick‑borne disease), following guideline‑based dosing. 4. Potential Adverse Effects Common or important adverse reactions can include: Gastrointestinal: Nausea, vomiting, diarrhea, abdominal discomfort. Dermatologic: Photosensitivity (increased sensitivity to sunlight), rash. Hematologic / Systemic: Rare hypersensitivity reactions, including severe cutaneous reactions and anaphylaxis. Infusion‑related: Pain, phlebitis, or irritation at the IV site. Superinfection: Use of broad‑spectrum antibiotics can promote overgrowth of non‑susceptible organisms, including Clostridioides difficile, leading to C. difficile–associated diarrhea/colitis. Any serious, unusual, or persistent adverse reaction should prompt medical evaluation and possible discontinuation. 5. Drug Interactions (Class Considerations) Clinicians should review full prescribing information and the patient’s medication profile for interactions, including: Anticoagulants (e.g., warfarin): Tetracyclines may potentiate effects; INR monitoring and dose adjustments may be necessary. Other hepatotoxic or nephrotoxic drugs: Concurrent use requires caution and monitoring. Penicillins: Tetracyclines may theoretically antagonize bactericidal activity of penicillins against some organisms; co‑administration requires clinical judgment. 6. Antimicrobial Stewardship Use should be based on documented or strongly suspected infection due to susceptible organisms. Therapy should be adjusted based on culture results, clinical response, and guideline recommendations. Unnecessary or prolonged use contributes to antimicrobial resistance and should be avoided. 7. Storage Store unreconstituted vials at controlled room temperature per manufacturer’s label (typically protected from excessive heat and light). Follow the official insert for: Storage conditions after reconstitution/dilution Maximum allowable time before use Requirements for protection from light or refrigeration, if applicable